CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Buspironedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03538431
NCT03538431Phase 4Completed
CompareCT.gov

Improving Driving in Young People With Autism Spectrum Disorders

Massachusetts General Hospital·interventional·Posted May 29, 2018·Updated Mar 18, 2021

In Brief

A Phase 4 clinical trial evaluating Buspirone for Autism Spectrum Disorder. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD). The study consists of an Assessment Visit at Massachusetts General Hospital (MGH), as well as two Driving Simulation visits that will take place at Massachusetts Institute of Technology (MIT). Subjects will be given buspirone and asked to take the medication for the two days preceding the Driving Simulation Visit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited States
CollaboratorsMassachusetts Institute of Technology

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMay 29, 2018
Enrollment StartOct 31, 2018
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.1 years ago

Interventions

Buspironedrug

Buspirone is an atypical anxiolytic medication.